A medical breakthrough was achieved by investigators who used a shorter course of Mavyret, or glecaprevir/pibrentasvir, plus Zetia, or ezetimibe, as a preventive regimen for hepatitis C virus infection in transplant recipients who received HCV-infected organs, according to results presented during the annual Liver Meeting of the American Association for the Study of Liver Diseases. "Expanding the donor pool is the big thing, and...the fact that you can cure hepatitis C with one week of treatment while in the hospital...it's paradigm-shifting, if it bears out," said AASLD press conference moderator Dr. Meena Bansal.
Mavyret, Zetia prevents HCV in transplantees with HCV-positive organs
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.